Platform Bispecific Antibody Technology

 Multi-Antigen T-Cell Hybridizers (MATCH) is a platform technology utilized to rapidly produce a library bispecific T-cell engagers. MATCH breaks down the traditional bispecific antibody into two components. Using a complementary morpholino oligonucleotide pair, the T-cell engaging component and self-assemble with the cancer cell engaging component in a one-to-one ratio. The resulting construct is a bispecific T-cell engager capable of recruiting and activating effector T-cells at the cancer cell surface. Synthesis of individual components is rapid and reproducible making MATCH a first-in-class multi-specific T-cell engaging technology. 

Advantages of MATCH include multi-specific targeting capability that allows for the creation of patient-specific targeting motif cocktails. Multi-specific targeting allows for better anti-cancer efficacy with the decreased chance of therapy-resistant relapse. Furthermore, the two-component nature of MATCH enables consecutive administration of the cancer cell engaging cocktail separate and distinct from the T-cell engaging dose. The two doses can be individually optimized based on number of cancer cells, number of available T-cells, and number of target receptors on the patient’s cancer cell surface.